Quantum Materials Corp. announced that in conjunction with its parent it has signed an agreement with MIG USA, for the inclusion of MIG USA and affiliates’ test kits in the QDX™ HealthID ecosystem. Additionally, the agreement allows for MIG USA to offer QDX™ HealthID to users of its test kits.  QDX™ HealthID, currently in beta release, is a SaaS-based platform that allows companies and individuals to see and select a particular COVID-19 test kit, authenticate and record the test results in a secure way, and then share those authenticated results with friends, family—or any other third party of their choosing.  MIG USA is awaiting FDA EUA approval for two rapid serology tests, to which MIG USA has distributor rights in the U.S. and several countries abroad. The agreement allows those persons registered on the QDX™ HealthID platform to use a MIG USA test kit — when a health care provider prescribes it. The agreement is non-exclusive and allows for other registered test kits and diagnostic services to be used by QDX™ HealthID customers. The agreement also allows for MIG USA to offer the QDX™ HealthID service to users of MIG USA’s and affiliates’ branded test kits. Initially, MIG USA’s employees will use QDX™ HealthID to create their health status. Additionally, MIG USA is including QDX™ HealthID as part of usability testing submission to the FDA. MIG USA is based in High Point, North Carolina. MIG USA and its subsidiaries and affiliates focus on the discovery, development, manufacturing and marketing of infectious disease screening and diagnostic products as well as contagion mitigation products. This agreement will allow for the parties’ expansion into a multitude of MIG USA product offerings and technologies which are synergistic with the vision for QDX™ HealthID.